Food and Drug Administration's Gastrointestinal Drugs Advisory Committee. September 15-16, 1988. The ACG Committee on FDA-related matters. American College of Gastroenterology.
Stern
W R
WR
D000527:Alprostadil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000636:Aminosalicylic Acids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000517:prevention & control; D004341:Drug Evaluation; D006801:Humans; D016595:Misoprostol; D013276:Stomach Ulcer / Q000139:chemically induced / Q000517:prevention & control*; D014481:United States; D014486:United States Food and Drug Administration
D000636:Aminosalicylic Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016595:Misoprostol; D000527:Alprostadil; C032587:olsalazine